A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff.

The portion of our nervous systems responsible for the "fight or flight" response can shape the severity of potentially deadly C. difficile infections, new research from the University of Virginia ...

10% upside for S&P 500. Piero Cingari This Clorox Analyst Believes There Is Downside To Estimates Clorox would need higher promotions amid a sequential decline in organic sales growth. Goldman ...

How Does Clorox P/E Compare to Other Companies? The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings ...

The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.

“C. diff is a really challenging pathogen,” said lead author Joseph Zackular, assistant professor of pathology and laboratory medicine at Penn. “This vaccine is kind of a really nice proof of ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

This image is AI-generated and does not depict any real ... the challenging Clostridioides difficile infection, researchers have revealed. Utilizing technology akin to that of COVID-19 vaccines, the ...